Guidelines and methodological reviews concerning drug abuse liability assessment

Robert L. Balster, George Bigelow

Research output: Contribution to journalArticle

Abstract

Regulatory control of drugs with abuse liability is an important component of drug control policy and is believed to help prevent nonmedical use. To be maximally effective, this requires a scientific assessment of abuse liability of drugs considered for regulatory control. These assessments have relied extensively on laboratory-based animal and human testing, but also utilize information from clinical trials, actual abuse and other sources. Here, we discuss recommendations and guidelines that have been proposed for abuse liability assessment and describe important review papers and conference proceedings that have addressed this matter, focusing primarily on drugs with medical usefulness. Historically, there is substantial consensus about how to approach abuse liability evaluation of drugs with actions similar to those of abused opiates, stimulants, depressants, and to a somewhat lesser extent, cannabinoids and hallucinogens, and much of what has been recommended for abuse potential assessment in the past remains valid and useful. On the other hand, novel CNS-active medications which cannot be readily classified with these traditional drugs of abuse are increasingly under development. In addition, advances in the science of abuse liability assessment need to be incorporated into future guidelines and recommendations on this subject. Developers of new medications need guidance on how to utilize scientific research to maximize therapeutic benefit while minimizing risk for abuse. Thus, another goal of this review has been to identify areas where critical thinking and new guideline development are needed.

Original languageEnglish (US)
JournalDrug and Alcohol Dependence
Volume70
Issue number3 SUPPL.
DOIs
StatePublished - Jun 5 2003

Fingerprint

drug abuse
liability
Substance-Related Disorders
abuse
Guidelines
Opiate Alkaloids
Pharmaceutical Preparations
drug
Hallucinogens
Drug Evaluation
Needs Assessment
Cannabinoids
Drug and Narcotic Control
Laboratory Animals
Street Drugs
Consensus
Clinical Trials
medication
Research
Animals

Keywords

  • Abuse liability
  • Drug discrimination
  • Physical dependence
  • Review
  • Self-administration
  • Subjective effects

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Guidelines and methodological reviews concerning drug abuse liability assessment. / Balster, Robert L.; Bigelow, George.

In: Drug and Alcohol Dependence, Vol. 70, No. 3 SUPPL., 05.06.2003.

Research output: Contribution to journalArticle

@article{74f5086c4a594844bb4dd1b1b2f1afc4,
title = "Guidelines and methodological reviews concerning drug abuse liability assessment",
abstract = "Regulatory control of drugs with abuse liability is an important component of drug control policy and is believed to help prevent nonmedical use. To be maximally effective, this requires a scientific assessment of abuse liability of drugs considered for regulatory control. These assessments have relied extensively on laboratory-based animal and human testing, but also utilize information from clinical trials, actual abuse and other sources. Here, we discuss recommendations and guidelines that have been proposed for abuse liability assessment and describe important review papers and conference proceedings that have addressed this matter, focusing primarily on drugs with medical usefulness. Historically, there is substantial consensus about how to approach abuse liability evaluation of drugs with actions similar to those of abused opiates, stimulants, depressants, and to a somewhat lesser extent, cannabinoids and hallucinogens, and much of what has been recommended for abuse potential assessment in the past remains valid and useful. On the other hand, novel CNS-active medications which cannot be readily classified with these traditional drugs of abuse are increasingly under development. In addition, advances in the science of abuse liability assessment need to be incorporated into future guidelines and recommendations on this subject. Developers of new medications need guidance on how to utilize scientific research to maximize therapeutic benefit while minimizing risk for abuse. Thus, another goal of this review has been to identify areas where critical thinking and new guideline development are needed.",
keywords = "Abuse liability, Drug discrimination, Physical dependence, Review, Self-administration, Subjective effects",
author = "Balster, {Robert L.} and George Bigelow",
year = "2003",
month = "6",
day = "5",
doi = "10.1016/S0376-8716(03)00097-8",
language = "English (US)",
volume = "70",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Guidelines and methodological reviews concerning drug abuse liability assessment

AU - Balster, Robert L.

AU - Bigelow, George

PY - 2003/6/5

Y1 - 2003/6/5

N2 - Regulatory control of drugs with abuse liability is an important component of drug control policy and is believed to help prevent nonmedical use. To be maximally effective, this requires a scientific assessment of abuse liability of drugs considered for regulatory control. These assessments have relied extensively on laboratory-based animal and human testing, but also utilize information from clinical trials, actual abuse and other sources. Here, we discuss recommendations and guidelines that have been proposed for abuse liability assessment and describe important review papers and conference proceedings that have addressed this matter, focusing primarily on drugs with medical usefulness. Historically, there is substantial consensus about how to approach abuse liability evaluation of drugs with actions similar to those of abused opiates, stimulants, depressants, and to a somewhat lesser extent, cannabinoids and hallucinogens, and much of what has been recommended for abuse potential assessment in the past remains valid and useful. On the other hand, novel CNS-active medications which cannot be readily classified with these traditional drugs of abuse are increasingly under development. In addition, advances in the science of abuse liability assessment need to be incorporated into future guidelines and recommendations on this subject. Developers of new medications need guidance on how to utilize scientific research to maximize therapeutic benefit while minimizing risk for abuse. Thus, another goal of this review has been to identify areas where critical thinking and new guideline development are needed.

AB - Regulatory control of drugs with abuse liability is an important component of drug control policy and is believed to help prevent nonmedical use. To be maximally effective, this requires a scientific assessment of abuse liability of drugs considered for regulatory control. These assessments have relied extensively on laboratory-based animal and human testing, but also utilize information from clinical trials, actual abuse and other sources. Here, we discuss recommendations and guidelines that have been proposed for abuse liability assessment and describe important review papers and conference proceedings that have addressed this matter, focusing primarily on drugs with medical usefulness. Historically, there is substantial consensus about how to approach abuse liability evaluation of drugs with actions similar to those of abused opiates, stimulants, depressants, and to a somewhat lesser extent, cannabinoids and hallucinogens, and much of what has been recommended for abuse potential assessment in the past remains valid and useful. On the other hand, novel CNS-active medications which cannot be readily classified with these traditional drugs of abuse are increasingly under development. In addition, advances in the science of abuse liability assessment need to be incorporated into future guidelines and recommendations on this subject. Developers of new medications need guidance on how to utilize scientific research to maximize therapeutic benefit while minimizing risk for abuse. Thus, another goal of this review has been to identify areas where critical thinking and new guideline development are needed.

KW - Abuse liability

KW - Drug discrimination

KW - Physical dependence

KW - Review

KW - Self-administration

KW - Subjective effects

UR - http://www.scopus.com/inward/record.url?scp=0037648825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037648825&partnerID=8YFLogxK

U2 - 10.1016/S0376-8716(03)00097-8

DO - 10.1016/S0376-8716(03)00097-8

M3 - Article

C2 - 12759195

AN - SCOPUS:0037648825

VL - 70

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 3 SUPPL.

ER -